These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 3725869)

  • 21. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulations.
    Pargal A; Kelkar MG; Nayak PJ
    Biopharm Drug Dispos; 1996 Aug; 17(6):511-9. PubMed ID: 8866042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation].
    Zhong D; Huang H; Wang A; Tian L; Lei X; Zhang J
    Yao Xue Xue Bao; 1998 Aug; 33(8):621-5. PubMed ID: 12016904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1997 Jun; 47(6):755-7. PubMed ID: 9239455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
    Deroubaix X; Lins RL; Lens S; Demblon C; Jeanbaptiste B; Poelaert D; Stockis A
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):61-70. PubMed ID: 8929748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules.
    Michos N; Zulliger HW; Barkworth MF; Johnson KJ; Rehm KD; Töberich H; Klein G
    Arzneimittelforschung; 1986 Jun; 36(6):941-8. PubMed ID: 3741528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the bioequivalence of 4- and 8-mg benidipine tablets in healthy volunteers after a single oral dose.
    Kang WK; Yun HY; Kwon KI
    J Clin Pharm Ther; 2005 Feb; 30(1):85-90. PubMed ID: 15659008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of indomethacin tablets in men volunteers.
    Groth PE; Dunn JM
    Clin Pharm; 1986 Oct; 5(10):820-4. PubMed ID: 3780150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absolute bioavailability of quinine formulations in Nigeria.
    Babalola CP; Bolaji OO; Ogunbona FA; Ezeomah E
    Afr J Med Med Sci; 2004 Sep; 33(3):185-9. PubMed ID: 15819461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers.
    Hatorp V; Oliver S; Su CA
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):636-41. PubMed ID: 9877000
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced bioavailability of triazolam following sublingual versus oral administration.
    Scavone JM; Greenblatt DJ; Friedman H; Shader RI
    J Clin Pharmacol; 1986 Mar; 26(3):208-10. PubMed ID: 3958225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative bioavailability and pharmacokinetics of hydrochlorothiazide from oral tablet dosage forms, determined by plasma level and urinary excretion methods.
    Barbhaiya RH; Patel RB; Corrick-West HP; Joslin RS; Welling PG
    Biopharm Drug Dispos; 1982; 3(4):329-36. PubMed ID: 7159688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitive assay for triazolam in plasma following low oral doses.
    Edeki T; Robin DW; Prakash C; Blair IA; Wood AJ
    J Chromatogr; 1992 May; 577(1):190-4. PubMed ID: 1400742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of three isoniazid formulations.
    Sved S; McGilveray IJ; Beaudoin N
    J Pharm Sci; 1977 Dec; 66(12):1761-4. PubMed ID: 925945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioavailability of acetazolamide tablets.
    Yakatan GJ; Frome EL; Leonard RG; Shah AC; Doluisio JT
    J Pharm Sci; 1978 Feb; 67(2):252-6. PubMed ID: 579636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxychloroquine relative bioavailability: within subject reproducibility.
    Tett S; Day R; Cutler D
    Br J Clin Pharmacol; 1996 Mar; 41(3):244-6. PubMed ID: 8866926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioreceptor assay and radioimmunoassay of triazolam in urine samples from racing greyhounds.
    Burnett JE; Oliver JS; Smith H
    Forensic Sci Int; 1989; 43(2):199-205. PubMed ID: 2606415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.
    Kroboth PD; Smith RB; Silver MR; Rault R; Sorkin MI; Puschett JB; Juhl RP
    Br J Clin Pharmacol; 1985 Jun; 19(6):839-42. PubMed ID: 2862896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay.
    Aaltonen L; Allonen H; Iisalo E; Juhakoski A; Kleimola T; Sellman R
    Acta Pharmacol Toxicol (Copenh); 1984 Aug; 55(2):100-3. PubMed ID: 6496110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary excretion profiles of two major triazolam metabolites, alpha-hydroxytriazolam and 4-hydroxytriazolam.
    Tsujikawa K; Kuwayama K; Miyaguchi H; Kanamori T; Iwata Y; Inoue H; Kishi T
    J Anal Toxicol; 2005; 29(4):240-3. PubMed ID: 15975253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioavailability of two oral formulations of triazolam using radioreceptor assay.
    Lapka R; Cepeláková H; Rejholec V; Franc Z
    Pharmazie; 1986 Apr; 41(4):256-7. PubMed ID: 3725869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.